Palatin deal

Palatin extended to April 30 the expiration of an option granted in 2013 to an undisclosed European specialty pharma to acquire rights to bremelanotide for female sexual dysfunction (FSD) in the EU and other undisclosed European countries. The option was originally set to expire in 1Q14. Palatin said the extension will allow the potential partner to complete a market assessment.

Palatin said the parties received "positive and clear" regulatory advice from EMA on Phase III testing for bremelanotide in FSD (see BioCentury, Nov. 18, 2013). ...